PMID- 25618448
OWN - NLM
STAT- MEDLINE
DCOM- 20151207
LR  - 20150321
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 24
IP  - 4
DP  - 2015 Apr
TI  - Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term 
      prognostic marker in heart failure with reduced ejection fraction.
PG  - 359-67
LID - S1443-9506(14)00741-0 [pii]
LID - 10.1016/j.hlc.2014.10.008 [doi]
AB  - BACKGROUND: The level of copeptin, a stable fragment of pro-arginine-vasopressin 
      (AVP), correlates with disease severity. It is an established, short-term 
      prognostic marker for patients with heart failure with reduced ejection fraction 
      (HFREF). We aimed to examine the association between copeptin and long-term 
      mortality. We also studied the clinical usefulness of copeptin as a prognostic 
      biomarker by analysing the improvement of net reclassification. METHODS: Copeptin 
      concentrations were measured in a cohort of 195 consecutive patients with HFREF. 
      Disease severity and clinical parameters were determined at baseline, and 
      all-cause mortality was recorded after five-year follow-up. RESULTS: One hundred 
      and ten patients died during the five-year follow-up (five-year mortality rate: 
      0.56). Univariate analysis identified copeptin (HR 2.168 [95% CI 1.740-2.700]) as 
      a predictor of mortality. The final, multivariable Cox survival model identified 
      a number of independent predictors of death. These included higher NHYA 
      functional class, previous MI, at least one hospitalisation for worsening HF 
      (within the two years before inclusion into the study), elevated blood urea 
      nitrogen, NT-proBNP-, and copeptin levels, as well as increased red blood cell 
      distribution width, and decreased GFR. The addition of copeptin alone to the 
      baseline predictive model (NT-proBNP only) resulted in a minor (8.21%) 
      improvement, whereas the final, multivariable model showed a significant increase 
      in net reclassification (10.26%, p=0.015). CONCLUSIONS: These data indicate that 
      copeptin is an independent long-term prognostic marker in HFREF, with possible 
      clinical relevance for multimarker risk prediction algorithms.
CI  - Copyright (c) 2014 Australian and New Zealand Society of Cardiac and Thoracic 
      Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). 
      Published by Elsevier B.V. All rights reserved.
FAU - Pozsonyi, Zoltan
AU  - Pozsonyi Z
AD  - 3(rd) Department of Internal Medicine, Semmelweis University, Kutvolgyi ut 4, 
      Budapest, H-1114, Hungary. Electronic address: pzoltan@kut.sote.hu.
FAU - Forhecz, Zsolt
AU  - Forhecz Z
AD  - 3(rd) Department of Internal Medicine, Semmelweis University, Kutvolgyi ut 4, 
      Budapest, H-1114, Hungary.
FAU - Gombos, Timea
AU  - Gombos T
AD  - 3(rd) Department of Internal Medicine, Semmelweis University, Kutvolgyi ut 4, 
      Budapest, H-1114, Hungary.
FAU - Karadi, Istvan
AU  - Karadi I
AD  - 3(rd) Department of Internal Medicine, Semmelweis University, Kutvolgyi ut 4, 
      Budapest, H-1114, Hungary.
FAU - Janoskuti, Livia
AU  - Janoskuti L
AD  - 3(rd) Department of Internal Medicine, Semmelweis University, Kutvolgyi ut 4, 
      Budapest, H-1114, Hungary.
FAU - Prohaszka, Zoltan
AU  - Prohaszka Z
AD  - 3(rd) Department of Internal Medicine, Semmelweis University, Kutvolgyi ut 4, 
      Budapest, H-1114, Hungary.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141113
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - 0 (Biomarkers)
RN  - 0 (Glycopeptides)
RN  - 0 (copeptins)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Glycopeptides/*blood
MH  - Heart Failure/*blood/*mortality/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - *Stroke Volume
MH  - Survival Rate
OTO - NOTNLM
OT  - B-type natriuretic peptide
OT  - Copeptin
OT  - Heart failure
OT  - Mortality
OT  - Vasopressin
EDAT- 2015/01/27 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/01/26 06:00
PHST- 2013/08/05 00:00 [received]
PHST- 2014/07/15 00:00 [revised]
PHST- 2014/10/21 00:00 [accepted]
PHST- 2015/01/26 06:00 [entrez]
PHST- 2015/01/27 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1443-9506(14)00741-0 [pii]
AID - 10.1016/j.hlc.2014.10.008 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2015 Apr;24(4):359-67. doi: 10.1016/j.hlc.2014.10.008. Epub 2014 
      Nov 13.